Roche, Regeneron join forces on COVID-19 antibody
Despite hundreds of potential therapies for COVID-19 looking to make their case, very few have crossed the finish line. One promising candidate, Regeneron's two-antibody cocktail, has earned early plaudits—and now a pharma giant is jumping aboard to boost manufacturing in a big way.
Regeneron will team up with Swiss drugmaker Roche to more than triple production of the New York biotech's COVID-19 antibody therapy, REGN-COV2, for a planned global rollout, the partners said Wednesday.
Under a seven-year licensing deal, Regeneron and Roche will each reserve manufacturing capacity for the therapy in preparation for future regulatory approvals, with Regeneron handling the U.S. rollout and Roche taking on distribution elsewhere.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-21
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India’s API Trade Balance Turns Positive
-
BioNTech’s Founders Turn the Page
-
Novo Nordisk Faces a Compliance Test
-
Pfizer Lifts 2025 Profit Forecast After Q2 Earnings Beat Sales Hit $14.65 Billion Shares Jump 2.8 Percent
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
Vertex Shares Plunge 14.4 Percent After Pain Drug Trial Misses Key Target and Study Halt
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
Recommend Reading
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
NHU and Sinopec Advance Liquid Methionine Project
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
International Oil Prices Experience a "Heart-Stopping Day" as U.S.-Iran Tensions Trigger Massive Shockwaves in the Energy Market
-
Weather Themes Remain; Palm Oil Futures Expected to Rise
-
Polyester Bottle Flakes Slightly Lowered on May 13, Showing Weak and Volatile Trends
-
Premium Global Chemical Sourcing Requests (11-13May, 2026)
-
This week, the price of anhydrous hydrogen fluoride remained high and stable in China (5.11-5.13)